The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
